伊伐布雷定增加心房颤动发生的可能机制及临床应用注意事项  

Research progress of ivabradine in increasing the occurrence of atrial fibrillation and clinical application precautions

作　　者：张占欣 高学英 肖冰[1] 刘凡[1] 鲁静朝[1] Zhang Zhanxin;Gao Xueying;Xiao Bing;Liu Fan;Lu Jingchao(Second Division,Department of Cardiology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院心血管内二科,石家庄050000

出　　处：《中国心血管杂志》2022年第5期486-490,共5页Chinese Journal of Cardiovascular Medicine

摘　　要：伊伐布雷定在降低窦性心律下心力衰竭或冠心病患者的心室率方面有明显益处。但临床实践提示,伊伐布雷定的应用会增加非心房颤动(房颤)患者的房颤发生风险。基于相关临床和基础研究证据,本文将系统阐述伊伐布雷定增加房颤发生风险的可能机制,并为伊伐布雷定的临床应用提供注意事项。Ivabradine has a clear benefit in reducing ventricular rate in patients with heart failure or coronary heart disease in sinus rhythm.However,clinical practice suggests that,the application of ivabradine will increase the risk of atrial fibrillation in non-atrial fibrillation patients.Based on relevant clinical studies and basic research evidence,we will systematically elaborate the mechanism hypothesis of ivabradine increasing the risk of atrial fibrillation,and provide considerations for its clinical practice.

关 键 词：心房颤动 伊伐布雷定 起搏电流 超极化激活环核苷酸阳离子门控通道 

分 类 号：R541.75[医药卫生—心血管疾病]